Mylan shareholders vote against executive pay package, but re-elect board

At the company’s annual meeting, Mylan (NSDQ:MYL) shareholders re-elected the drugmaker’s board despite a campaign spearheaded by major investors to do otherwise.
The campaign hoped to encourage shareholders to vote down most of the board’s directors in response to Mylan’s drug pricing practices for its EpiPen device. The influential proxy advisory firm, ISS, also urged shareholders last week to vote against the directors.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan shareholders vote against executive pay package, but re-elect board appeared first on MassDevice.

Source: Mass Device - June 22, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Wall Street Beat Mylan Sanofi-Aventis Source Type: news